Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Export

@article{citeulike:4891956, abstract = {A cyclophosphamide (Cy)-resistant immunogenic tumour, the L5178Y lymphoma, was used to demonstrate that Cy-treatment of a host bearing this tumour enables passively transferred tumour-sensitized T cells to cause complete tumour regression without any need for Cy to cause a reduction in tumour burden. It was shown that whereas infusion of tumour-sensitized T cells from immune donors had very little effect on growth of the tumour, and whereas treatment with 150 mg/kg of Cy caused appreciable enhancement of tumour growth, combination therapy with Cy plus immune T cells caused complete tumour regression and resulted in long-term survival. Evidence that Cy treatment facilitated the expression of adoptive immunity against the L5178Y lymphoma by eliminating tumour-induced suppressor T cells consisted of the demonstration that tumour regression caused by combination treatment with Cy and immune T cells could be inhibited by infusing the recipient with Cy-sensitive, L3T4+ T cells from tumour-bearing but not from normal donors.}, author = {Awwad, M. and North, R. J.}, citeulike-article-id = {4891956}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/2972604}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=2972604}, issn = {0019-2805}, journal = {Immunology}, keywords = {chemotherapy, removal, superlist, thelist, treg, tumor}, month = {September}, number = {1}, pages = {87--92}, posted-at = {2009-06-18 13:47:55}, priority = {2}, title = {Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/2972604}, volume = {65}, year = {1988} }

TY - JOUR ID - citeulike:4891956 L3 - citeulike-article-id:4891956 N2 - A cyclophosphamide (Cy)-resistant immunogenic tumour, the L5178Y lymphoma, was used to demonstrate that Cy-treatment of a host bearing this tumour enables passively transferred tumour-sensitized T cells to cause complete tumour regression without any need for Cy to cause a reduction in tumour burden. It was shown that whereas infusion of tumour-sensitized T cells from immune donors had very little effect on growth of the tumour, and whereas treatment with 150 mg/kg of Cy caused appreciable enhancement of tumour growth, combination therapy with Cy plus immune T cells caused complete tumour regression and resulted in long-term survival. Evidence that Cy treatment facilitated the expression of adoptive immunity against the L5178Y lymphoma by eliminating tumour-induced suppressor T cells consisted of the demonstration that tumour regression caused by combination treatment with Cy and immune T cells could be inhibited by infusing the recipient with Cy-sensitive, L3T4+ T cells from tumour-bearing but not from normal donors. IS - 1 JF - Immunology SN - 0019-2805 EP - 92 TI - Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. VL - 65 SP - 87 KW - chemotherapy KW - removal KW - superlist KW - thelist KW - treg KW - tumor AU - Awwad, M AU - North, RJ PY - 1988/09// UR - http://view.ncbi.nlm.nih.gov/pubmed/2972604 ER -